title: Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause.
abstract: Unlike parenteral estrogens, oral estrogen administration in menopause causes, through its hepatocellular action, a significant decrease of circulating insulin-like growth factor I (IGF-I) levels; this effect is opposed by the addition of an androgenic progestogen. In vitro studies show that IGF-I is a potent mitogen for 'estrogen responsive' breast cancer cells. Moreover, some findings in breast cancer patients and in women treated with tamoxifen suggest that reduction of circulating IGF-I could be protective to the breast. However, by also considering (1) the potential action on breast cancer cells of IGF-II, (2) the possible consequences of the growth hormone (GH) increase caused by the IGF-I reduction and (3) the fact that in vitro results are not simply transferable to the in vivo condition, other 'scenarios' can be envisaged, besides the favorable one. In support of the latter, there are epidemiologic data which suggest that oral estrogen use could have some favorable peculiarities with regards to breast cancer risk. The associated decrease in circulating IGF-I level could well be one of these peculiarities.
authors.affiliation: Department of Endocrinologic Gynecology, Sant'Anna Gynecologic Hospital, Turin, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Campagnoli
authors.forename: N
authors.initials: N
authors.lastname: Biglia
authors.forename: C
authors.initials: C
authors.lastname: Peris
authors.forename: P
authors.initials: P
authors.lastname: Sismondi
mesh_terms: D001943:Breast Neoplasms / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D008593:Menopause / Q000097:blood*; D011372:Progestins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D011372:Progestins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone